Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 12, 1998

View Archived Issues

Company Profile: Vivus

Dainippon in-licenses Wakunaga fluoroquinolone

Bio-Technology General establishes Eastern European licensing agreement for recombinant insulin

Endorex, Elan agree to form joint venture for vaccine development

Merck continues to devote extensive R&D efforts to FTase inhibitors

Japanese launch announced for HIV protease inhibitor

Good in vitro activity reported for Novartis PKC inhibitor

First clinical results reported for SC-68240

Cell adhesion inhibitors from Merck KGaA

Chiroscience synthesizes new MMP/TNF-inhibitory agents

Ketoacid ETA antagonists from Warner-Lambert

Novel thalidomide prodrugs reported in patent literature

Neurogen describes D3 receptor-specific ligands

Novel binding mechanism described for Shin Nippon's H+/K+-ATPase inhibitor

Phase I/II results reported for Searle's new hematopoietic growth factor

New mycotoxin with antitumor and favorable hematological effects

New hematopoietic growth factor family presented

Effects of neutrophil elastase inhibitor MDL-101146 in two arthritis models

More dopamine receptor ligands from Merck & Co.

Diatide's acute thrombosis imaging agent scheduled for review by FDA panel

New urinary incontinence product from Biomatrix cleared for clinical trials

New antiviral peptides from Boehringer Ingelheim

Arris completes acquisition of Sequana

FDA approves Photofrin for early-stage lung cancer

Two SBIR grants awarded to Cubist for antiinfective drug discovery

Anti-HIV fusion inhibitor from Trimeris advances to phase II

CDK inhibitor induces apoptosis and tumor necrosis in a dog with malignant melanoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...